Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus STILPHOSTROL.
NORGESTIMATE AND ETHINYL ESTRADIOL vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via estrogen receptor; norgestimate is a progestin that inhibits ovulation and thickens cervical mucus.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
One tablet (norgestimate 0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days followed by 7 placebo tablets.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Norgestimate: ~21.3 hours (range 16-36 hours); active metabolite 17-deacetyl norgestimate: ~33.2 hours (range 22-45 hours). Ethinyl estradiol: ~17.1 hours (range 14-22 hours). Terminal half-life supports once-daily dosing; steady-state achieved within 10-14 days.
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Urine (primarily as glucuronide and sulfate conjugates; ~50-60% of dose), feces (~30-40% of dose as metabolites), minimal unchanged drug in urine
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category D/X
Category C
Estrogen
Estrogen